Compare IDEXX Laboratories, Inc. (IDXX) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs LYFT Inc — how do they compare? IDEXX Laboratories, Inc. trades at $571.66 (market cap $46.22B), while LYFT Inc trades at $16.52 (market cap $6.64B). The key difference: IDEXX Laboratories, Inc. is far larger — about 7× LYFT Inc's market cap, and LYFT Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | LYFT | |
|---|---|---|
Market Cap | $46.22B | $6.64B |
Sector | Health | Industrials |
52-Week High | $766.68 | $24.57 |
52-Week Low | $526.44 | $12.65 |
Enterprise Value | $47.12B | $6.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Lyft trades at $17.26, down 1.15% today, with strong technical momentum showing bullish moving averages but overbought RSI signals. The company demonstrates remarkable fundamental improvement with 2025 revenue reaching $6.32B and net income surging to $2.84B, achieving a 45% profit margin. Recent Q2 2026 results showed revenue growth of 16.1% with record active riders exceeding 30 million, though earnings slightly missed estimates amid higher costs.
Lyft presents a compelling turnaround story with accelerating profitability and market share gains against Uber, supported by expanding robotaxi partnerships and international growth. However, elevated valuation multiples, competitive pressures, and ongoing legal scrutiny create headwinds. With analyst consensus at $19.17 representing 11% upside potential, the stock offers growth exposure but requires monitoring of execution risks and expense management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
